These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9241663)

  • 1. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies.
    Schulz WA; Krummeck A; Rösinger I; Eickelmann P; Neuhaus C; Ebert T; Schmitz-Dräger BJ; Sies H
    Pharmacogenetics; 1997 Jun; 7(3):235-9. PubMed ID: 9241663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci.
    Clairmont A; Sies H; Ramachandran S; Lear JT; Smith AG; Bowers B; Jones PW; Fryer AA; Strange RC
    Carcinogenesis; 1999 Jul; 20(7):1235-40. PubMed ID: 10383895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations.
    Gaedigk A; Tyndale RF; Jurima-Romet M; Sellers EM; Grant DM; Leeder JS
    Pharmacogenetics; 1998 Aug; 8(4):305-13. PubMed ID: 9731717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and susceptibility to esophageal cancer].
    Zhang JH; Li Y; Wang R; Sarbia M; Guo W; Wen DG; Wei LZ; Chen ZF; Kuang G; Zhang LW; He M; Wu ML; Wang SJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Dec; 20(6):544-6. PubMed ID: 14669229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy.
    Toncheva DI; Von Ahsen N; Atanasova SY; Dimitrov TG; Armstrong VW; Oellerich M
    J Nephrol; 2004; 17(3):384-9. PubMed ID: 15365958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking.
    Rosvold EA; McGlynn KA; Lustbader ED; Buetow KH
    Pharmacogenetics; 1995 Aug; 5(4):199-206. PubMed ID: 8528266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predisposition towards urolithiasis associated with the NQO1 null-allele.
    Schulz WA; Krummeck A; Rösinger I; Schmitz-Dräger BJ; Sies H
    Pharmacogenetics; 1998 Oct; 8(5):453-4. PubMed ID: 9825838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases alpha and pi in human renal cell carcinoma and in kidney cancer-derived cell lines.
    Eickelmann P; Ebert T; Warskulat U; Schulz WA; Sies H
    Carcinogenesis; 1994 Feb; 15(2):219-25. PubMed ID: 8313512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
    Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
    Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 609 C --> T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia.
    Steiner M; Hillenbrand M; Borkowsi M; Seiter H; Schuff-Werner P
    Cancer Lett; 1999 Jan; 135(1):67-71. PubMed ID: 10077223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of GSTT1, GSTM1 and NQO1 (609C>T) in Filipino children with ALL (acute lymphoblastic leukaemia).
    Rimando MG; Chua MN; Yuson Ed; de Castro-Bernas G; Okamoto T
    Biosci Rep; 2008 Jun; 28(3):117-24. PubMed ID: 18444911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese.
    Hamajima N; Matsuo K; Iwata H; Shinoda M; Yamamura Y; Kato T; Hatooka S; Mitsudomi T; Suyama M; Kagami Y; Ogura M; Ando M; Sugimura Y; Tajima K
    Int J Clin Oncol; 2002 Apr; 7(2):103-8. PubMed ID: 12018106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer.
    Harth V; Donat S; Ko Y; Abel J; Vetter H; Brüning T
    Arch Toxicol; 2000 Jan; 73(10-11):528-31. PubMed ID: 10663383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects.
    Akkiz H; Bayram S; Bekar A; Akgöllü E; Ülger Y; Kaya BY; Sandikçi M; Özdil B
    Asian Pac J Cancer Prev; 2010; 11(4):1051-8. PubMed ID: 21133623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association analyses between polymorphisms of the phase II detoxification enzymes (GSTM1, NQO1, NQO2) and alcohol withdrawal symptoms.
    Okubo T; Harada S; Higuchi S; Matsushita S
    Alcohol Clin Exp Res; 2003 Aug; 27(8 Suppl):68S-71S. PubMed ID: 12960511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia.
    Sirma S; Agaoglu L; Yildiz I; Cayli D; Horgusluoglu E; Anak S; Yuksel L; Unuvar A; Celkan T; Apak H; Karakas Z; Devecioglu O; Ozbek U
    Pediatr Blood Cancer; 2004 Oct; 43(5):568-70. PubMed ID: 15382274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of bladder cancer risk with an NAD(P)H:quinone oxidoreductase polymorphism in an ethnic Kashmiri population.
    Pandith AA; Khan NP; Shah ZA; Shah AM; Wani SM; Siddiqi MA
    Biochem Genet; 2011 Aug; 49(7-8):417-26. PubMed ID: 21253823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line.
    Eickelmann P; Schulz WA; Rohde D; Schmitz-Dräger B; Sies H
    Biol Chem Hoppe Seyler; 1994 Jul; 375(7):439-45. PubMed ID: 7945992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population.
    Lewis SJ; Cherry NM; Niven RM; Barber PV; Povey AC
    Lung Cancer; 2001 Nov; 34(2):177-83. PubMed ID: 11679176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements.
    Lanciotti M; Dufour C; Corral L; Di Michele P; Pigullo S; De Rossi G; Basso G; Leszl A; Luciani M; Lo Nigro L; Micalizzi C; Valsecchi MG; Biondi A; Haupt R
    Leukemia; 2005 Feb; 19(2):214-6. PubMed ID: 15618957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.